Coughlin Timothy
SEC CIK 1376043 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| TVTX | Travere Therapeutics, Inc. | Dir | 66.2K | — | $1.27M | 10 | 2022-05-11 | 2026-06-12 |
| VIR | Vir Biotechnology, Inc. | Dir | 16.0K | — | — | 1 | 2026-06-09 | 2026-06-09 |
| ADCT | ADC Therapeutics SA | Dir | 72.4K | — | — | 3 | 2025-06-03 | 2026-06-03 |
| ATYR | aTYR PHARMA INC | Dir | 56.0K | $87.5K | — | 4 | 2023-04-26 | 2024-05-30 |
| FATE | FATE THERAPEUTICS INC | Dir | 9,892 | — | $32.8K | 2 | 2022-06-03 | 2022-06-09 |
Most active insiders at TVTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Dube Eric M | CEO, Dir | — | $41.35M |
| 2 | Heerma Peter | EVP, Chief COMMERCIAL Off | — | $18.97M |
| 3 | ROTE WILLIAM E. | Chief Research Off | — | $16.43M |
| 4 | REED ELIZABETH E | CLO, GC | — | $7.02M |
| 5 | Inrig Jula | EVP, CMO, Head of R, D | — | $5.16M |
| 6 | Cline Christopher R. | CFO | — | $4.64M |
| 7 | Calvin Sandra | SVP, CAO | — | $4.19M |
| 8 | Baynes Roy D. | Dir | — | $2.55M |
| 9 | Meckler Jeffrey A | Dir | — | $1.71M |
| 10 | Coughlin Timothy | Dir | — | $1.27M |
Transactions 20
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-16 16:46 | 2026-06-12 | TVTX | Travere Therapeutics, Inc. | Coughlin Timothy | Dir | M - OptEx | $26.52 | +10.0K | 66.2K | +18% | +$265.2K |
| DT | 2026-06-16 16:46 | 2026-06-12 | TVTX | Travere Therapeutics, Inc. | Coughlin Timothy | Dir | S - Sale+OE | $50.07 | -10.0K | 56.2K | -15% | -$500.7K |
| DM | 2026-06-10 18:21 | 2026-06-09 | VIR | Vir Biotechnology, Inc. | Coughlin Timothy | Dir | A - Grant | $0.00 | +16.0K | 16.0K | New | $0 |
| 2026-06-03 17:02 | 2026-06-01 | ADCT | ADC Therapeutics SA | Coughlin Timothy | Dir | A - Grant | $0.00 | +45.0K | 85.0K | +112% | $0 | |
| 2026-06-03 17:02 | 2026-06-03 | ADCT | ADC Therapeutics SA | Coughlin Timothy | Dir | F - Tax | $3.08 | -12.6K | 72.4K | -15% | -$38.8K | |
| D | 2026-05-21 17:00 | 2026-05-19 | TVTX | Travere Therapeutics, Inc. | Coughlin Timothy | Dir | A - Grant | $0.00 | +4,000 | 56.2K | +8% | $0 |
| T | 2026-05-19 16:05 | 2026-05-15 | TVTX | Travere Therapeutics, Inc. | Coughlin Timothy | Dir | S - Sale | $43.49 | -3,250 | 52.2K | -6% | -$141.3K |
| DM | 2025-11-04 | 2025-10-31 | TVTX | Travere Therapeutics, Inc. | Coughlin Timothy | Dir | M - OptEx | $16.95 | +18.0K | 63.5K | +40% | +$305.0K |
| D | 2025-11-04 | 2025-10-31 | TVTX | Travere Therapeutics, Inc. | Coughlin Timothy | Dir | S - Sale+OE | $35.03 | -18.0K | 55.5K | -24% | -$630.5K |
| D | 2025-06-05 | 2025-06-03 | ADCT | ADC Therapeutics SA | COUGHLIN TIMOTHY | Dir | A - Grant | $0.00 | +40.0K | 40.0K | New | $0 |
| D | 2025-05-16 | 2025-05-15 | TVTX | Travere Therapeutics, Inc. | COUGHLIN TIMOTHY | Dir | A - Grant | $0.00 | +6,500 | 55.5K | +13% | $0 |
| I | 2024-06-03 | 2024-05-30 | ATYR | aTYR PHARMA INC | COUGHLIN TIMOTHY | Dir | P - Purchase | $1.75 | +50.0K | 56.0K | +833% | +$87.5K |
| D | 2024-05-10 | 2024-05-08 | TVTX | Travere Therapeutics, Inc. | COUGHLIN TIMOTHY | Dir | A - Grant | $0.00 | +6,500 | 49.0K | +15% | $0 |
| D | 2023-05-19 | 2023-05-17 | TVTX | Travere Therapeutics, Inc. | COUGHLIN TIMOTHY | Dir | A - Grant | $0.00 | +4,500 | 42.5K | +12% | $0 |
| DI | 2023-05-19 | 2023-05-17 | ATYR | aTYR PHARMA INC | COUGHLIN TIMOTHY | Dir | G - Gift | $0.00 | +6,000 | 6,000 | New | $0 |
| D | 2023-05-19 | 2023-05-17 | ATYR | aTYR PHARMA INC | COUGHLIN TIMOTHY | Dir | G - Gift | $0.00 | -6,000 | 0 | -100% | $0 |
| D | 2023-04-28 | 2023-04-26 | ATYR | aTYR PHARMA INC | COUGHLIN TIMOTHY | Dir | M - OptEx | — | +6,000 | 6,000 | New | — |
| D | 2022-06-13 | 2022-06-09 | FATE | FATE THERAPEUTICS INC | COUGHLIN TIMOTHY | Dir | A - Grant | $0.00 | +8,650 | 9,892 | +696% | $0 |
| 2022-06-06 | 2022-06-03 | FATE | FATE THERAPEUTICS INC | COUGHLIN TIMOTHY | Dir | S - Sale | $22.81 | -1,439 | 57.6K | -2% | -$32.8K | |
| D | 2022-05-12 | 2022-05-11 | TVTX | Travere Therapeutics, Inc. | COUGHLIN TIMOTHY | Dir | A - Grant | $0.00 | +3,000 | 38.0K | +9% | $0 |
Purchase Sale Sale after option exercise All abbreviations